The Broad Institute's Metabolomics Platform undertakes systematic studies of metabolites, the unique chemical fingerprints that result from both normal and pathological cellular processes.
Because of their immediacy to cell physiology, metabolites are promising biomarkers for disease, as well as clues to genetic or drug alterations in the cell.
The Metabolomics Platform undertakes both discovery- and hypothesis-driven studies in collaboration with researchers across the Broad and external research communities. Current projects include the discovery of early metabolic markers of predisposition to type 2 diabetes, characterization of mitochondrial disorders, and elucidating metabolic networks in cellular studies of cancer metabolism, infectious disease, and metabolic disorders.
The platform is directed by Clary Clish, an expert in metabolite profiling and liquid chromatography tandem mass spectrometry.